Pharvaris reports 83% HAE attack reduction in latest trial results

• Pharvaris reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo.
• The global trial enrolled 85 adolescents and adults, with all primary and secondary efficacy endpoints achieving statistical significance.
• Pharvaris plans to use the results to support regulatory submissions, including a U.S. New Drug Application in the first half of 2027.

Pharvaris (NASDAQ:PHVS) reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo across all HAE types after 24 weeks.

The global, double-blind, placebo-controlled study enrolled 85 adolescents and adults with hereditary angioedema and randomized participants 2:1 to receive deucrictibant XR 40 mg or placebo.

The company reported that the treatment reduced attacks by 87% among 80 participants with HAE Type 1 or Type 2, while the primary endpoint and all secondary efficacy endpoints achieved statistical significance.

Pharvaris reported that deucrictibant XR showed early protection during the first week of treatment and maintained benefits through 24 weeks, with no treatment-related serious adverse events and one discontinuation in each study arm.

Pharvaris develops oral therapies for hereditary angioedema and said it plans to use CHAPTER-3 data to support marketing applications, including a U.S. NDA submission in the first half of 2027.